Table 4.
Summary of the outcomes of published studies of PRDR.
| Study | Number of Patients |
Diagnosis | Median Previous Radiotherapy Dose (Gy) |
Median PRDR Re-irradiation Dose (Gy) |
Cumulative Dose (Gy) | Median Target Volume (cm3) | Median Time from Previous Radiotherapy to PRDR (months) | Median PFS | Median OS | Side Effects |
|---|---|---|---|---|---|---|---|---|---|---|
| Adkison 2011 [11] | 103 | Low grade glioma: 25, Grade 3 glioma: 31, Grade 4 glioma: 45, Brainstem glioma: 1, Pineal tumor:1 |
59.4 (range: 50.4–72.5) | 50 (range: 22–58) | 106.8 | 369.2 (range: 89.6–1002.2) | 18.2 (range: 2–227.6) | NA | 5.8 months (range: 1–48.4 months) | 4 (3.9%) radiation necrosis |
| Magnuson 2014 [13] | 23 | Grade 4 glioma | 60 (range: 59.4–60) | 54 | 114 | 424 (range: 74–776) | 11.8 (range: 6.8–36.8) | 3.7 months (range: 1.2–14.1 months) | 6.9 months (range: 2.7–12 months) | Zero grade 3+ toxicity |
| Mohindra 2014 [14] | 5 | Ependymoma | 48.4 (range: 36–55.8) | 40 (range: 30.6–54) | 105.2 (range: 90–162.4) | Mean portal area of 348 cm2 | 58 months (range: 32–212 months) | 34 months (95% CI: 11–57 months) | 64 months (95% CI: 8–120 months) | Zero grade 3+ toxicity Zero radiation necrosis |
| Murphy 2017 [15] | 24 | Grade 2: 4, Grade 3: 10, Grade 4: 8, NA: 2 |
59.7 (range: 38–60) | 54 (range: 38–60) | 113.7 (range: 97.4–120), 1 patient got PRDR twice: 169.2 Gy | Mean: 369.1 +/− 177.9 | 47.8 months (range: 11–389.1 months) | 3.1 months | 8.7 months | Total 20 (18.1%) side effects, Zero radiation necrosis |
| Bovi 2020 [12] | 33 patients bevacizumab + PRDR | Grade 3: 14,Grade 4: 19 | NA | 50–54 | NA | NA | NA | 12 months (95% CI: 10–16 months) |
16 months (95% Cl: 15–21 months) |
NA |